Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Autozone Inc (AZO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Autozone Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Autozone Inc trades at $3,060.2 (market cap $50.20B). The key difference: Autozone Inc is far larger — about 11.2× ACADIA Pharmaceuticals Inc.'s market cap, and Autozone Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | AZO | |
|---|---|---|
Market Cap | $4.49B | $50.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $4.35K |
52-Week Low | $20.06 | $2.94K |
Enterprise Value | $3.69B | $62.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AutoZone (AZO) trades at $3,074.86, down 2.67% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though profit margins have declined from 14.94% in 2022 to 13.19% in 2025. Recent Q1 2026 earnings beat expectations at $38.07 EPS versus $36.22 expected, while the board authorized an additional $1.5B stock repurchase in June 2026.
AZO presents a mixed outlook with 72.7% analyst buy ratings and $3,740 consensus target suggesting 21.6% upside, but faces technical headwinds and margin compression risks. Investment appeal hinges on international expansion execution and commercial segment growth offsetting domestic softness noted in recent earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
